Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(24):1820-1821; doi:10.1093/jnci/95.24.1820
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brower, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

Epoetin for Cancer Patients: A Boon or a Danger?

Vicki Brower

The first 10% of the full text of this article appears below.

New clinical and basic research with erythropoietin, or epoetin, is raising questions about whether the red blood cell growth factor, often given to cancer patients with chemotherapy-associated anemia and fatigue, might actually encourage cancer growth. Two recent trials of epoetin in cancer patients showed that it negatively affected survival, and a growing body of research by Harvard University scientists and others indicates that some cancer cells possess epoetin receptors that respond to exogenous epoetin by accelerating the growth and proliferation of certain cancer cells in vitro. And, as this issue of the Journal went to press, Johnson & Johnson announced that it was stopping a number of trials of its drug Procrit (epoetin alfa) because of a higher-than-expected . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. Lindholm, P. Daneryd, U. Korner, A. Hyltander, M. Fouladiun, and K. Lundholm
Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients
Clin. Cancer Res., October 15, 2004; 10(20): 6855 - 6864.
[Abstract] [Full Text] [PDF]